Acid stable liposomal compositions and methods for producing the same
The present invention relates to a liposomal formulation for oral delivery of a bioactive agent that considers pH stability and oxidative stability of a bioactive ingredient. These lipid formulations are superior to conventional liposomes due to their stability, thereby circumventing the need for intra-venous delivery of bioactive agents. In one embodiment, the methods and compositions of the present invention relate to the oral delivery of insulin or a prodrug thereof.
1. A liposomal formulation comprising 1,2-di-O-hexadecyl-sn-glycero-3-phosphatidylcholine and 1,2-di-O-phytanyl-sn-glycero-3-phosphatidylethanolamine, wherein the 1,2-di-O-hexadecyl-sn-glycero-3-phosphatidylcholine and 1,2-di-O-phytanyl-sn-glycero-3-phosphatidylethanolamine form uniformly sized particles; wherein the molar ratio of 1,2-di-O-hexadecyl-sn-glycero-3-phosphatidylcholine: 1,2-di-O-phytanyl-sn-glycero-3-phosphatidylethanolamine of the formulation is in the range of 2:1 to 2:3; and wherein the liposomal formulation is stable at a pH of at least 1.
2. The liposomal formulation of claim 1 , wherein the particles comprise: liposomes, nanoliposomes, niosomes, microspheres, nanospheres, nanoparticles, micelles or archaeosomes.
3. The liposomal formulation of claim 2 , wherein the uniformly-sized particles encapsulate a bioactive agent.
4. The liposomal formulation of claim 3 , wherein the bioactive agent is insulin or a pro-drug thereof.
5. The liposomal formulation of claim 3 , having a molar ratio of: 1,2-di-O-hexadecyl-sn-glycero-3-phosphatidylcholine, 1,2-di-O-phytanyl-sn-glycero-3-phosphatidylethanolamine and bioactive agent of 6:3:1.
6. The liposomal formulation of claim 3 , wherein the bioactive agent is docosahexanoic acid (DHA).
7. The liposomal formulation of claim 3 , wherein the uniformly-sized particles further comprise a PEGylated lipid.
8. The liposomal formulation of claim 7 , wherein the uniformly-sized particles comprise up to 20 molar percent of the PEGylated lipid.
9. The liposomal formulation of claim 7 , wherein the PEGylated lipid is 1,2-di-O-phytanyl-sn-glycero-3-phosphatidylethanolamine-PEG2000.
10. The liposomal formulation of claim 7 , wherein the PEGylated lipid is 1,2 distearoyl-phosphatidylethanolamine-PEG2000.
11. The liposomal formulation of claim 7 , wherein the formulation has a molar ratio of 1,2-di-O-hexadecyl-sn-glycero-3-phosphatidylcholine: 1,2-di-O-phytanyl-sn-glycero-3-phosphatidylethanolamine: PEGylated lipid of 5:3:2.
12. The liposomal formulation of claim 7 , wherein the formulation has a molar ratio of: 1,2-di-O-hexadecyl-sn-glycero-3-phosphatidylcholine: 1,2-di-O-phytanyl-sn-glycero-3-phosphatidylethanolamine: PEGylated lipid of 4.5:4.0:1.5.